Constantin Tamvakopoulos

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2216089/publications.pdf

Version: 2024-02-01

57 papers	2,196 citations	304368 22 h-index	223531 46 g-index
57 all docs	57 docs citations	57 times ranked	3078 citing authors

#	Article	IF	Citations
1	Integrin-Mediated Targeted Cancer Therapy Using c(RGDyK)-Based Conjugates of Gemcitabine. Journal of Medicinal Chemistry, 2022, 65, 271-284.	2.9	6
2	Treatment and prevention of pathological mitochondrial dysfunction in retinal degeneration and in photoreceptor injury. Biochemical Pharmacology, 2022, 203, 115168.	2.0	10
3	Development of programmable gemcitabine-GnRH pro-drugs bearing linker controllable â€œclickâ€•oxime bond tethers and preclinical evaluation against prostate cancer. European Journal of Medicinal Chemistry, 2021, 211, 113018.	2.6	20
4	Discovery and Pharmacological Evaluation of STEAP4 as a Novel Target for HER2 Overexpressing Breast Cancer. Frontiers in Oncology, 2021, 11, 608201.	1.3	12
5	Immunotherapy Combined with Metronomic Dosing: An Effective Approach for the Treatment of NSCLC. Cancers, 2021, 13, 1901.	1.7	13
6	Pathogenic mitochondrial dysfunction and metabolic abnormalities. Biochemical Pharmacology, 2021, 193, 114809.	2.0	21
7	Design, synthesis and biological evaluation of novel substituted purine isosters as EGFR kinase inhibitors, with promising pharmacokinetic profile and inÂvivo efficacy. European Journal of Medicinal Chemistry, 2019, 176, 393-409.	2.6	13
8	Development of bioactive gemcitabine-D-Lys6-GnRH prodrugs with linker-controllable drug release rate and enhanced biopharmaceutical profile. European Journal of Medicinal Chemistry, 2019, 166, 256-266.	2.6	15
9	Dexamethasone induces Ï‰3-derived immunoresolvents driving resolution of allergic airway inflammation. Journal of Allergy and Clinical Immunology, 2018, 142, 691-695.e4.	1.5	30
10	Abstract LB-262: Design, synthesis, and efficacy of MYC inhibitors in mouse pancreatic cancer. , 2018, , .		0
11	Gemcitabine Based Peptide Conjugate with Improved Metabolic Properties and Dual Mode of Efficacy. Molecular Pharmaceutics, 2017, 14, 674-685.	2.3	19
12	Versatile quarto stimuli nanostructure based on Trojan Horse approach for cancer therapy: Synthesis, characterization, in vitro and in vivo studies. Materials Science and Engineering C, 2017, 79, 605-612.	3.8	11
13	Nurr1:RXRÎ± heterodimer activation as monotherapy for Parkinsonâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3999-4004.	3.3	61
14	Design and synthesis of novel 7-aminosubstituted pyrido[2,3-b]pyrazines exhibiting anti-breast cancer activity. European Journal of Medicinal Chemistry, 2017, 126, 954-968.	2.6	10
15	Targeting of the breast cancer microenvironment with a potent and linkable oxindole based antiangiogenic small molecule. Oncotarget, 2017, 8, 37250-37262.	0.8	5
16	Discovery of New Aminosubstituted Pyrrolopyrimidines with Antiproliferative Activity Against Breast Cancer Cells and Investigation of their Effect Towards the PI3KÎ± Enzyme. Anti-Cancer Agents in Medicinal Chemistry, 2017, 17, 990-1002.	0.9	3
17	Abstract 230: Proteomic approaches in the discovery of novel drug targets or potential biomarkers in breast cancer. , 2017, , .		0
18	Peptideâ€“Drug Conjugate GnRHâ€“Sunitinib Targets Angiogenesis Selectively at the Site of Action to Inhibit Tumor Growth. Cancer Research, 2016, 76, 1181-1192.	0.4	24

#	Article	IF	Citations
19	Abstract 2618: Gemcitabine based peptide conjugates: Overcoming the pitfalls of conventional therapies by targeted approaches. , 2015, , .		0
20	Abstract LB-260: A small molecule Myc inhibitor has therapeutic effects on mouse pancreatic and other cancers. , 2015, , .		0
21	Abstract B42: Therapeutic effects of an anti-myc drug on mouse pancreatic cancer. , 2015, , .		0
22	Therapeutic Effects of an Anti-Myc Drug on Mouse Pancreatic Cancer. Journal of the National Cancer Institute, 2014, 106, .	3.0	66
23	Chemoembolization of Hepatocellular Carcinoma with Hepasphere 30â€“60ÂÎ¼m. Safety and Efficacy Study. CardioVascular and Interventional Radiology, 2014, 37, 165-175.	0.9	97
24	GnRH-Gemcitabine Conjugates for the Treatment of Androgen-Independent Prostate Cancer: Pharmacokinetic Enhancements Combined with Targeted Drug Delivery. Bioconjugate Chemistry, 2014, 25, 813-823.	1.8	43
25	Transarterial Embolization with Sorafenib in Animal Livers: A Pharmacokinetics Study. Journal of Vascular and Interventional Radiology, 2013, 24, 1657-1663.e1.	0.2	12
26	Tollâ€like receptor 7 stimulates production of specialized proâ€resolving lipid mediators and promotes resolution of airway inflammation. EMBO Molecular Medicine, 2013, 5, 762-775.	3.3	62
27	Rationally designed cyclic analogues of luteinizing hormone-releasing hormone: Enhanced enzymatic stability and biological properties. European Journal of Medicinal Chemistry, 2012, 58, 237-247.	2.6	14
28	Peptide and protein drugs: The study of their metabolism and catabolism by mass spectrometry. Mass Spectrometry Reviews, 2012, 31, 110-133.	2.8	62
29	Oral Administration of Chios Mastic Gum or Extracts in Mice: Quantification of Triterpenic Acids by Liquid Chromatography-Tandem Mass Spectrometry. Planta Medica, 2011, 77, 1916-1923.	0.7	17
30	Discovery of a piperazine urea based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor partial agonist. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2330-2334.	1.0	16
31	Evaluation of a Stable Gonadotropin-Releasing Hormone Analog in Mice for the Treatment of Endocrine Disorders and Prostate Cancer. Journal of Pharmacology and Experimental Therapeutics, 2011, 336, 613-623.	1.3	17
32	Discovery of substituted biphenyl imidazoles as potent, bioavailable bombesin receptor subtype-3 agonists. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1913-1917.	1.0	21
33	Discovery of a spiroindane based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor agonist. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2106-2110.	1.0	20
34	Synthesis and SAR of derivatives based on 2-biarylethylimidazole as bombesin receptor subtype-3 (BRS-3) agonists for the treatment of obesity. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2074-2077.	1.0	26
35	Synthesis and SAR of heterocyclic carboxylic acid isosteres based on 2-biarylethylimidazole as bombesin receptor subtype-3 (BRS-3) agonists for the treatment of obesity. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2912-2915.	1.0	21
36	Optimization of privileged structures for selective and potent melanocortin subtype-4 receptor ligands. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4483-4486.	1.0	7

#	Article	IF	Citations
37	Spiroindane based amides as potent and selective MC4R agonists for the treatment of obesity. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4399-4405.	1.0	14
38	Discovery of potent, selective, and orally bioavailable 3H-spiro[isobenzofuran-1,4â€²-piperidine] based melanocortin subtype-4 receptor agonists. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4895-4900.	1.0	11
39	Discovery of highly potent and efficacious MC4R agonists with spiroindane N-Me-1,2,4-triazole privileged structures for the treatment of obesity. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6524-6532.	1.0	19
40	Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis. Arthritis Research and Therapy, 2010, 12, R147.	1.6	69
41	Simultaneous Absolute Quantification of the Glucose-Dependent Insulinotropic Polypeptides GIP_{1â^'42} and GIP_{3â^'42} in Mouse Plasma by LC/ESI-MS/MS: Preclinical Evaluation of DP-IV Inhibitors. Journal of Proteome Research, 2009, 8, 3487-3496.	1.8	15
42	In vivo evaluation and in vitro metabolism of leuprolide in miceâ€"mass spectrometryâ€based biomarker measurement for efficacy and toxicity. Journal of Mass Spectrometry, 2008, 43, 1381-1392.	0.7	33
43	Synthesis and SAR of potent and orally bioavailable tert-butylpyrrolidine archetype derived melanocortin subtype-4 receptor modulators. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3242-3247.	1.0	17
44	Discovery of potent, orally active benzimidazole glucagon receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3701-3705.	1.0	35
45	Search for Potential Markers for Prostate Cancer Diagnosis, Prognosis and Treatment in Clinical Tissue Specimens Using Amine-Specific Isobaric Tagging (iTRAQ) with Two-Dimensional Liquid Chromatography and Tandem Mass Spectrometry. Journal of Proteome Research, 2008, 7, 3146-3158.	1.8	92
46	Metabolism and Anticancer Activity of the Curcumin Analogue, Dimethoxycurcumin. Clinical Cancer Research, 2007, 13, 1269-1277.	3.2	173
47	Mass spectrometry for the quantification of bioactive peptides in biological fluids. Mass Spectrometry Reviews, 2007, 26, 389-402.	2.8	65
48	A liquid chromatographic/tandem mass spectroscopic method for quantification of the cyclic peptide melanotanâ€II. Plasma and brain tissue concentrations following administration in mice. Rapid Communications in Mass Spectrometry, 2007, 21, 2431-2438.	0.7	20
49	Analysis of thein vitro metabolites of diferuloylmethane (curcumin) by liquid chromatography â€" tandem mass spectrometry on a hybrid quadrupole linear ion trap system: newly identified metabolites. European Journal of Drug Metabolism and Pharmacokinetics, 2007, 32, 51-57.	0.6	12
50	Discovery of (2S)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl-2-pip (MB243), a potent and selective melanocortin subtype-4 receptor agonist. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 171-175.	1.0	47
51	1-Amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid as a Tic mimetic: Application in the synthesis of potent human melanocortin-4 receptor selective agonists. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3430-3433.	1.0	16
52	Discovery and activity of (1R,4S,6R)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-methy (3, RY764), a potent and selective melanocortin subtype-4 receptor agonist. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3501-3505.	1.0	39
53	Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4564-4569.	1.0	42
54	2-Piperazinecarboxamides as potent and selective melanocortin subtype-4 receptor agonists. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1993-1996.	1.0	22

#	Article	IF	Citations
55	The Role of Dipeptidyl Peptidase IV in the Cleavage of Glucagon Family Peptides. Journal of Biological Chemistry, 2003, 278, 22418-22423.	1.6	205
56	A role for the melanocortin 4 receptor in sexual function. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11381-11386.	3.3	289
57	Design and Pharmacology ofN-[(3R)-1,2,3,4-Tetrahydroisoquinolinium-3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol-) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 662 Td (1-ylmet Agonist. Journal of Medicinal Chemistry, 2002, 45, 4589-4593.	2.9	187